Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Income from Continuing Operations (2016 - 2025)

Seres Therapeutics' Income from Continuing Operations history spans 11 years, with the latest figure at 21859000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 23.35% year-over-year to 21859000.0; the TTM value through Sep 2025 reached 100593000.0, up 53.05%, while the annual FY2024 figure was 117348000.0, 38.32% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 21859000.0 at Seres Therapeutics, up from 24335000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 68253000.0 in Q3 2021 and bottomed at 124669000.0 in Q4 2023.
  • The 5-year median for Income from Continuing Operations is 33408000.0 (2024), against an average of 32895052.63.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 322.87% in 2021 before it crashed 5574.51% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 49685000.0 in 2021, then surged by 95.58% to 2197000.0 in 2022, then plummeted by 5574.51% to 124669000.0 in 2023, then surged by 77.72% to 27781000.0 in 2024, then grew by 21.32% to 21859000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Income from Continuing Operations are 21859000.0 (Q3 2025), 24335000.0 (Q2 2025), and 26618000.0 (Q1 2025).